NRIX Stock Overview
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.
Nurix Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.86|
|52 Week High||US$32.18|
|52 Week Low||US$7.52|
|1 Month Change||-1.74%|
|3 Month Change||-23.14%|
|1 Year Change||-60.55%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-37.61%|
Recent News & Updates
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth CarefullyJun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business GrowthMar 07
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In GrowthNov 21
We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash BurnJul 24
Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn SituationApr 15
Industry Analysts Just Upgraded Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Revenue Forecasts By 10%Feb 21
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Are Pretty Bullish On The Stock After Recent ResultsFeb 18
Rainbows and Unicorns: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Became A Lot More OptimisticJan 31
|NRIX||US Biotechs||US Market|
Return vs Industry: NRIX underperformed the US Biotechs industry which returned -13.5% over the past year.
Return vs Market: NRIX underperformed the US Market which returned -20.2% over the past year.
|NRIX Average Weekly Movement||9.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: NRIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: NRIX's weekly volatility (9%) has been stable over the past year.
About the Company
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer.
Nurix Therapeutics, Inc. Fundamentals Summary
|NRIX fundamental statistics|
Is NRIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NRIX income statement (TTM)|
|Cost of Revenue||US$174.92m|
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.63|
|Net Profit Margin||-436.66%|
How did NRIX perform over the long term?See historical performance and comparison